

A structured review of health utility measures and elicitation in advanced/metastatic breast cancer

Yanni Hao¹
Verena Wolfram²
Jennifer Cook²

¹Novartis Pharmaceuticals, East Hanover, NJ, USA; ²Adelphi Values, Bollington, UK

Background: Health utilities are increasingly incorporated in health economic evaluations. Different elicitation methods, direct and indirect, have been established in the past. This study examined the evidence on health utility elicitation previously reported in advanced/metastatic breast cancer and aimed to link these results to requirements of reimbursement bodies.

Methods: Searches were conducted using a detailed search strategy across several electronic databases (MEDLINE, EMBASE, Cochrane Library, and EconLit databases), online sources (Cost-effectiveness Analysis Registry and the Health Economics Research Center), and web sites of health technology assessment (HTA) bodies. Publications were selected based on the search strategy and the overall study objectives.

Results: A total of 768 publications were identified in the searches, and 26 publications, comprising 18 journal articles and eight submissions to HTA bodies, were included in the evidence review. Most journal articles derived utilities from the European Quality of Life Five-Dimensions questionnaire (EQ-5D). Other utility measures, such as the direct methods standard gamble (SG), time trade-off (TTO), and visual analog scale (VAS), were less frequently used. Several studies described mapping algorithms to generate utilities from disease-specific health-related quality of life (HRQOL) instruments such as European Organization for Research and Treatment of Cancer Quality of Life Questionnaire – Core 30 (EORTC QLQ-C30), European Organization for Research and Treatment of Cancer Quality of Life Questionnaire – Breast Cancer 23 (EORTC QLQ-BR23), Functional Assessment of Cancer Therapy – General questionnaire (FACT-G), and Utility-Based Questionnaire-Cancer (UBQ-C); most used EQ-5D as the reference. Sociodemographic factors that affect health utilities, such as age, sex, income, and education, as well as disease progression, choice of utility elicitation method, and country settings, were identified within the journal articles. Most submissions to HTA bodies obtained utility values from the literature rather than exploring the HRQOL data obtained during clinical development. This was critiqued by the National Institute for Health and Clinical Excellence (NICE). Furthermore, the impact of age on utilities was highlighted by NICE and it was suggested that an age match of the study population should be attempted.

Conclusion: Health utilities are recorded across the globe to varying extents and using differing elicitation methods. Manufacturers seeking reimbursement need to be aware of the country-specific requirements for elicitation of health utilities.

Keywords: health utilities, advanced/metastatic breast cancer, health-related quality of life, health technology assessment, HTA, direct utility measures, indirect utility measures

Correspondence: Jennifer Cook
Adelphi Values, Adelphi Mill, Bollington,
Macclesfield, Cheshire SK10 5JB, UK
Tel +44 1625 577 256
Fax +44 1625 577 328
Email jennifer.cook@adelphivalues.com

Background

Breast cancer is the most commonly diagnosed cancer among women worldwide, one in eight women being diagnosed in their lifetime in the US¹; in Europe, 464,000 new



cases are estimated to have been diagnosed in 2012, 13.5% of all cancer cases.² Approximately 5%–10% of breast cancers diagnosed are metastatic/advanced in nature, and of these, approximately one-fifth survive for a period extending up to 5 years.³ Although significant advances in treatment have been made in recent years, metastatic/advanced breast cancer continues to provide challenges for the health care system.⁴ In addition, disease recurrence at a distant metastatic site is common, occurring in as many as 30% of women initially diagnosed with an earlier-stage breast cancer.⁵ The focus of this manuscript is on metastatic/advanced breast cancer.

Patients with breast cancer often undergo several rounds of treatment during which they endure adverse events and toxicity.^{6–8} This affects the health-related quality of life (HRQOL), which can be measured during trials using generic or disease-specific HRQOL instruments, such as the European Quality of Life Five-Dimensions questionnaire (EQ-5D) or the Functional Assessment of Cancer Therapy – General questionnaire (FACT-G), respectively. Breast cancer is associated with a decrease in HRQOL, particularly in patients with advanced/metastatic breast cancer.⁹

Reimbursement decision makers are interested in the efficacy of treatments, and economic analyses are increasingly being utilized when comparing care settings and treatment modalities. A cornerstone of such analysis is the quality-adjusted life year (QALY), which incorporates both the quantity and the quality of life (QOL) lived generated by health care interventions. QALYs are therefore the arithmetic product of life expectancy and a measure of the quality of the remaining life-years.¹⁰ QALYs are used in cost–utility analysis (CUA), in which cost of treatment is related to survival and QOL, and they are also used to support health technology assessment (HTA) submission and reimbursement decisions.

To facilitate calculation of QALYs, the QOL part has to be a health preference or health utility measure rated on a scale from 0 (dead) to 1 (full health).¹¹ Several approaches have been developed to elicit health utilities. Direct measures such as time trade-off (TTO) and standard gamble (SG) can be used for discrete condition-specific health states. The visual analog scale (VAS) method is another commonly used direct measure.

On the other hand, indirect measures utilize validated HRQOL instruments, either generic (eg, EQ-5D) or disease-specific (eg, FACT-G), for well-defined health states. As HRQOL instruments do not directly return utility values, an algorithm is necessary to assign values to the responses from a social tariff or value set, which can be derived from patients or the general population using TTO or SG. The

choice of health utility measure often depends on several factors; the study question, mode of action of a therapy, the impact on the patient, the availability of country-specific guidelines detailing what is acceptable, and whether the aim is to support clinical or policy decisions, are factors that can potentially influence the choice of measure.

The preferred utility elicitation method, as also outlined by the European Network for Health Technology Assessment (EUnetHTA) guidelines,¹² in several European countries is indirect elicitation using the generic EQ-5D. This tool enables comparability of interventions across different technologies and disease areas. It is further recommended that the used value set be based on preferences representing the general population. However, TTO is considered appropriate/acceptable by some HTA bodies when EQ-5D is not appropriate.¹³ Valuation of the health states by the general public is recommended, as resource allocation in a publically funded health care system should be weighted by the general public's perception of disease burden. Because perception of disease burden can vary among the population due to experience as well as sociodemographic factors (eg, age, sex, education, and income), utilities could be affected by these factors.

The objective of this study was two-fold: to identify health utility measures previously used in advanced/metastatic breast cancer, and to understand how these factors may influence future economic evaluations of metastatic/advanced cancer therapies. This article reports on the results obtained from a broad review of the published literature and health economic databases and thereafter aims to link these results to the requirements of reimbursement bodies to support decision making.

Methods

A targeted literature search was conducted electronically to identify international publications relating to health utilities in advanced/metastatic breast cancer. The following databases were used in OVID (OVID Technologies, Inc); MEDLINE and MEDLINE (R) In-Process (PubMed), EMBASE (OVID), EconLit (EBSCOhost), and the National Health Service (NHS) Economic Evaluation Database (NHS-EED). The search used a combination of disease-specific terms (breast cancer, metastatic, and advanced) and health utility-specific terms (standard gamble, time trade-off, EQ-5D, Health Utilities Index [HUI1, HUI2, HUI3], Short Form – Six-Dimension [SF-6D]) and their derivatives (such as SG for standard gamble). In addition, a search string was used to identify cost-effectiveness, cost utility, cost benefit, cost minimization, cost evaluation, or cost analysis studies [cost* adj2 (effective* Or utilit* Or ben-

efit* Or minimi* Or evaluat* Or analy*). “*” and “adj” are search commands utilized in the database search to increase both sensitivity and specificity of the searches. The search was limited to studies on humans published in English language only, between January 2005 and March 2015, to identify the most up-to-date literature. Studies for full-publication review were selected for inclusion on the basis of the search strategy and the overall objectives of the study. When determining the most relevant articles for full review, prioritization was given to publications placing greater emphasis on utility measure utilization as the primary objective.

In addition to the targeted literature review, a gray literature search was undertaken to identify supplementary evidence that would augment findings in areas not well reported in the published literature. Databases within which the gray literature search was conducted included the Cost-effectiveness Analysis (CEA) Registry, the Health Economics Research Center (HERC) database of mapping studies, and the database of the International Network of Agencies for Health Technology Assessment (INAHTA). A review of breast cancer product submission documents from HTA bodies in the UK (the National Institute for Health and Clinical Excellence [NICE], Scottish Medicines Consortium [SMC], and All Wales Medicines Strategy Group [AWMSG]) was also conducted to inform understanding of manufacturers’ different approaches in generating utility data in advanced/metastatic breast cancer and their acceptability by HTA bodies. In addition, EUnetHTA guidance documentation was reviewed to gain further insight from the wider European HTA perspective.¹²

An overview of the study methodology is presented in Figure 1.

Results

Summary of the literature review results

A total of 768 potentially relevant publications were identified in the searches; 748 were identified in the OVID search, 20 in the gray literature search, including ten HTA submissions. When assessed for inclusion, 26 studies/publications – 18 journal articles and eight HTA submissions – were deemed relevant as they contained material related to utility measures in advanced/metastatic breast cancer. Journal articles of studies that derived utility measures/values from the literature were excluded at the screening stage.

The journal articles reviewed in this review comprise studies that fall in three categories. The first category included studies (n=11) that use HRQOL measures, both generic (eg, EQ-5D) and disease specific, to describe patient health status/QOL and elicit health utilities with the potential use of these utilities in future economic evaluations.^{9,14–23} The second group comprised studies (n=3) that described the development and/or validation of mapping algorithms between disease-specific HRQOL measures and generic utility measures to predict breast cancer utility values from disease-specific HRQOL outcomes measures for use in future economic evaluations.^{24–26} The third category contained health economic evaluations (n=4), including cost–utility studies, which elicit health utilities during the study to be incorporated in a health economic model.^{27–30} A summary of the key findings from the literature review, detailing the main trends observed, is presented here.




Figure 1 Overview of methodology.

Abbreviations: AWMSG, All Wales Medicines Strategy Group; HTA, health technology assessment; INAHTA, International Network of Agencies for Health Technology Assessment; NICE, National Institute for Health and Clinical Excellence; SMC, Scottish Medicines Consortium.

Table 1 Utility and health-related quality of life measures reported in the identified journal articles

Reference	Generic measures			Direct measures			Disease-specific measures			UBQ-C	Utilities collected?	Mapping/conversion	Source of utility/HRQOL data
	EQ-5D	I5D	SF-6D	TTO	SG	VAS	FACT-G	FACT-B	EORTC QLQ-C30				
Studies focusing on HRQOL analyses to generate health utilities													
Frederix et al ¹⁴				✓							Yes; TTO only		the Netherlands: 100 individuals from general public; Sweden: 100 women aged ≥50 years from the general public
Grimison et al ¹⁵									✓		Yes		325 patients with breast cancer (advanced cancer trial); 126 patients with breast cancer (early cancer trial)
Haines et al ¹⁶	✓								✓		Yes; EQ-5D only		89 patients with newly diagnosed breast cancer
Kuchuk et al ¹⁷					✓						Yes		69 (of 102) patients with breast cancer
Lidgren et al ¹⁹	✓										Yes; EQ-5D and TTO only		361 (345 after exclusions) patients with breast cancer
Lloyd et al ¹⁸	✓										Yes; SG only		100 individuals; general population
Milne et al ¹⁹	✓										Yes		50 women; general population
Schleinitz et al ²⁰											Yes		156 women not undergoing treatment for breast cancer
Sherrill et al ²¹	✓										Yes		399 patients with advanced or metastatic HER2+ breast cancer
Shih et al ²²					✓						Yes		20 oncology nurses
Zhou et al ²³	✓										Yes; EQ-5D only		399 patients with advanced or metastatic HER2+ breast cancer (utilities were elicited from 331 patients)
Studies that map HRQOLs to utility measures													
Crott and Briggs ²⁶	✓										Yes		448 patients with locally advanced breast cancer (from the literature)
Kim et al ²⁵	✓										Yes		199 patients with metastatic breast cancer
Teckle et al ²⁴	✓										Yes		367 patients with cancer (patients with breast cancer = 140); population was subdivided into two samples: development (184) and cross-validation (183)

Cost-utility or cost-effectiveness analyses (calculating utilities)

Bastani and Kiadali ³⁰	✓	Yes	EORTC QLQ-C30 mapped to 15D and EQ-5D ^a	100 patients with node-positive breast cancer
Cheng et al ^{29,b}	✓	Yes, VS and SG only	Power conversion from VS to SG values	152 patients with stage Ia–IIa breast cancer
Dranitsaris et al ²⁸	✓	Yes		14 oncology nurses and ten pharmacists
Mansel et al ²⁷	✓	Yes		26 patients with early or advanced breast cancer

Notes: EORTC QLQ-C30 outcomes were mapped onto EQ-5D using a mapping algorithm previously developed for gastric cancer.⁴¹ Cheng et al²⁹ utilized a multiattribute utility scoring formula, based on SG utilities derived from the power conversion of VS (VAS) scores.

Abbreviations: EQ-5D, European Quality of Life Five-Dimensions questionnaire; 15D, 15-Dimensions questionnaire; SF-6D, Short Form – Six-Dimension; TTO, time trade-off; SG, standard gamble; VAS, visual analog scale; VS, visual scale; FACT-G, Functional Assessment of Cancer Therapy – General questionnaire; Fact-B, Functional Assessment of Cancer Therapy – Breast; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire – Core 30; EORTC QLQ-BR23, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire – Breast Cancer 23; UBQ-C, Utility-Based Questionnaire-Cancer; HRQOL, health-related quality of life; HER2, human epidermal growth factor receptor 2.

All the journal articles in the search strategy reported on breast cancer utility-related studies conducted in several countries across Europe, North America, Oceania, and Asia. A number of publications reported on studies conducted in more than one country.^{9,14–23} Most of the health utility data in the journal articles originated from observational/real-world studies. Only two journal articles that reported on elicitation of breast cancer utilities during clinical trials were identified.^{23,30}

The sample size in each of the 18 identified journal articles from which utilities were elicited varied widely, ranging from 20 to 448 respondents (Table 1). The utility values were obtained from patients, patient proxies, as well as from the general public. In most of the identified publications (n=12), utilities were obtained from patients with breast cancer at various stages of disease. A total of two studies generated utilities from oncology nurses as a patient proxy;^{22,28} of these, one study also generated utilities from pharmacists.²⁸ Additionally, authors of four studies generated their data from members of the general public.^{14,18–20}

The methods of data collection varied; however, data were most commonly collected during face-to-face interviews or using written questionnaires and surveys. When data were obtained from patients, it was generally during a scheduled clinic appointment or while patients were hospitalized. If follow-up interviews/questionnaires were part of the study design, these were scheduled at regular intervals and often based around subsequent appointments.

HRQOL measures and utility instruments used

Health utilities can be derived by indirect or direct measures. Across all journal articles, different elicitation methods were identified, with authors of several publications (n=12) using more than one health utility measure (Table 1).

Indirect measurement of health utilities can be performed by applying a utility algorithm to a generic preference-based measure. Two generic preference-based measures, EQ-5D and SF-6D, were identified in the included journal articles. EQ-5D was utilized in most studies (n=9),^{9,16,18,19,21,23–26} with eight studies deriving utility values from EQ-5D outcomes using country-specific social tariffs.^{9,16,19,21,23–26} Only one study reported the use of EQ-5D without deriving utility values from it.¹⁸ European countries are highly represented in studies using EQ-5D, but its use was also reported in studies on cohorts from countries including the US.^{21,23} SF-6D was used in a Canadian study alongside EQ-5D, and a disease-specific instrument, FACT-G, was used to explore mapping feasibilities.²⁴

Eight of the identified journal articles utilized disease-specific HRQOL instruments, including the cancer-specific FACT-G, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire – Core 30 (EORTC QLQ-C30), and Utility-Based Questionnaire-Cancer (UBQ-C), as well as breast cancer-specific FACT-B and EORTC QLQ – Breast Cancer 23 (EORTC QLQ-BR23) (Table 1). EORTC QLQ-C30 was the most commonly used instrument, used in five studies. Six of the eight studies used disease-specific instruments (EORTC QLQ-C30 and -BR23; FACT-G and -B) alongside EQ-5D or TTO-and-SG, and three studies subsequently mapped the responses to EQ-5D.^{24–26} Only one study, from Australia, reported use of the cancer-specific measure UBQ-C and the subscales were converted to a utility index.¹⁵

The direct elicitation tools SG and TTO have been identified in six^{17,18,20,22,27,29} and five^{9,14,19,20,28} journal articles, respectively. SG and TTO have mainly been used as the sole utility measures. One study used both measures, however, for different purposes; SG was used to derive utilities for five breast cancer disease states, while TTO was used to derive utilities for three new therapeutic modalities.²⁰ This cited study viewed TTO as being less complex than SG for assessing temporary health state utilities related to 1-year descriptions for treatment and recovery.²⁰ Additionally, TTO was used in two studies alongside EQ-5D^{9,19} to obtain utility values. This enabled Lidgren et al⁹ to describe the differences in utilities when using HRQOLs based on community preferences (EQ-5D social tariffs) versus those based on patient preferences (TTO). In this study, mean TTO utility values were higher for all four breast cancer disease states compared to the EQ-5D index values, three of which were statistically significant ($P < 0.05$).⁹ Similarly, Milne et al¹⁹ generated utilities in breast cancer using both a direct and an indirect method, allowing for analysis of the differences in utility values. The mean and the median utility valuations obtained by using the TTO method were generally higher for three of the four health states than those from other methods (EQ-5D and VAS).¹⁹

The VAS technique, otherwise known as the rating scale, is often used as a HRQOL measure and can be used to elicit utility values via conversion formulas. A total of nine publications reported on the use of VAS.^{9,14,16,18,19,22,23,25,29} In all of these, VAS was used in addition to other measures, mainly EQ-5D (often as EQ-5D VAS), but also TTO and SG. In only three publications was VAS used to derive the utility values by itself.^{19,22,29}

Mapping of disease-specific HRQOL measures to utility instruments

Disease-specific HRQOL measures are commonly used to evaluate HRQOL in patients with cancer. Utilities can also be obtained indirectly from disease-specific HRQOL measures, which can be more sensitive than generic ones. These measures do not have utility scoring systems and translating the HRQOL outcomes of these instruments into utility values requires mapping to preference-based measures, such as the EQ-5D questionnaire.²²

In three identified journal articles, mapping studies have been described with the aim of developing algorithms that can be used in future research.^{24–26} In these publications, different instruments have been administered in parallel and the results have been used to develop mapping algorithms. Crott and Briggs²⁶ developed algorithms to map the cancer-specific EORTC QLQ-C30 to EQ-5D, while Kim et al²⁵ mapped the cancer-specific EORTC QLQ-C30 as well as its breast cancer-specific module EORTC QLQ-BR23 to EQ-5D. The latter showed that EORTC QLQ-C30 was better suited to mapping to EQ-5D than EORTC QLQ-BR23 as errors in the first case were observed to be smaller. Teckle et al²⁴ mapped the cancer-specific questionnaire FACT-G to both EQ-5D and SF-6D, showing that mapping of FACT-G to either EQ-5D or SF-6D was feasible. An additional study used a mapping algorithm previously developed for gastric cancer to map EORTC QLQ-C30 to 15-Dimensions (15D) and EQ-5D in patients with breast cancer to evaluate the cost utility of adjuvant therapies.³⁰

Factors that might influence health utility values

Factors such as sociodemographic characteristics of the study population (eg, age and sex), disease progression, country setting, and choice of instrument influenced the magnitude of health utility values.

Sociodemographic factors

In order to assess the effect of intrapopulation differences on the elicited utilities, baseline sociodemographic factors, including age, sex, ethnicity, household income, education, and marital status, were analyzed in two studies.^{18,20}

The impact of age was investigated in both studies.^{18,20} Lloyd et al¹⁸ found that people aged 50 years rated stable metastatic disease on treatment with no side effects, a higher utility value than people aged 40 years (0.77 versus 0.72). In contrast, mean utility values for five breast cancer dis-

ease states in the study by Schleinitz et al²⁰ were lower for patients aged ≥ 50 years compared to those aged ≤ 50 years, albeit not statistically significant (eg, disease stage III: 0.51 versus 0.61). It should be noted that the health states are not comparable between these two publications. The impact of sex was identified in one study, with male participants showing greater decline in utility associated with disease progression compared to female participants.¹⁸ The authors suggested that female participants considered family responsibilities and child care more in rating health states and so were less willing to accept risks to avoid progression of disease.¹⁸ Ethnicity, household income, and education were also shown to influence utilities.²⁰ For example, results from the study by Schleinitz et al²⁰ showed that being black, having a household income of $< \$25,000$, or having less education resulted in lower utilities in less severe disease states (stages I–III).²⁰ This was statistically significant in one-way analysis of variance analysis (*P*-values for each disease stage ranged from < 0.001 to 0.01).²⁰ Mean utilities for hormonal treatment were demonstrated to be higher in white people than other ethnicities, while they were lower for those from a lower-income household.²⁰ Additionally, being single also resulted in lower mean utilities for all treatment options (chemotherapy, hormonal therapy, and radiation therapy).²⁰

Disease progression

Lidgren et al⁹ showed that disease progression affected utility values, with patients showing utilities of 0.901, 0.842, 0.889, and 0.820 for the first year after primary cancer, first year after recurrence, second and following years after primary cancer/recurrence, and metastatic disease, respectively. Schleinitz et al²⁰ demonstrated a similar pattern in which the overall mean utilities of less severe disease stages were higher compared to mean utilities in more severe disease stages (decrease from 0.68 in stage I of tumor, node, metastasis classification of the American Joint Committee on Cancer versus 0.41 in stage IV).

Instrument type

Comparing the performance of different elicitation methods showed that utility values varied between the methods. For example, mean TTO values were consistently higher than the mean EQ-5D values for all four defined disease states studied by Lidgren et al.⁹ The difference between the two sets of values was statistically significant for three of the four states.⁹

Country requirements

Differences among countries may result in differences in utility values. For example, in a study by Frederix et al,¹⁴ the TTO-derived utilities for nine breast cancer health states were collected from two different cohorts, one in the Netherlands and one in Sweden. Of these, the Swedish sample rated progressive and stable disease health states (0.61 and 0.81, respectively) higher than the Dutch sample (0.49 and 0.69, respectively).¹⁴ Frederix et al¹⁴ demonstrate that this is due to the fact that both countries have different reimbursement criteria when it pertains to utility collection. The Netherlands advocates preferences to be representative of the general public. In contrast, the Swedish reimbursement agencies prefer obtaining utilities from the same demography as people with the disease of interest, resulting in this cohort containing a larger number of older females.¹⁴

As the Swedish study population was generally older, they may have had a different perspective when they were asked to consider trading years of life in the TTO task compared to the younger Dutch sample. Furthermore, although utilities were not generated from EQ-5D outcomes, the Swedish cohort reported worse health status based on EQ-5D than the Dutch population. It is suggested by Frederix et al¹⁴ that older people are likely to be less concerned about the prospect of poor health states as they have already experienced poor health, resulting in higher preference weights for poor health states.¹⁴

HTA submission documents

A total of eight HTA documents submitted to NICE, AWMSG, or SMC contained information related to advanced/metastatic breast cancer utilities, along with comments from the HTA bodies. In all submissions, the manufacturer used SG-derived utilities obtained from the literature, most often from the study by Lloyd et al,¹⁸ in which utilities were collected from members of the UK general public ($n=100$). In five submissions, the manufacturer recorded HRQOL data (EQ-5D,³¹ FACT-B,^{32–34} and EORTC QLQ-C30)³⁵ during the clinical studies; however, only in two were utility values generated from these data.^{31,34} In one submission to the AWMSG, the manufacturer utilized EQ-5D administered during a trial to generate utility values,³¹ while one of the NICE submissions used a mapping algorithm to obtain utility values using FACT-B data obtained in their trial.³⁴ One submission did not detail the method utilized to generate utilities.³⁶

The main concerns of the appraisal committee and the evidence review group were 1) use of SG utility values from

the study by Lloyd et al,¹⁸ as the age of the population in that study¹⁸ did not match the age of patients with breast cancer or of the trial population, and 2) the absence of mapping of disease-specific HRQOL data to utility indexes.³⁵ Additionally, the NICE committee was concerned about omission of adverse event disutilities from base-case models.^{37,38}

In addition, the National Institute for Health Research HTA database, detailing submission of documents from members of the INAHTA and other HTA organizations, was searched. No HTA submissions relevant to advanced/metastatic breast cancer utilities were identified.

Discussion

Overall, a limited number of publications were identified that reported elicitation of health utilities in advanced/metastatic breast cancer. However, the identified publications reported on studies across the globe, with most utilizing EQ-5D for health utility elicitation.

As a generic measure, EQ-5D can be used for a broad range of diseases, enabling comparisons across disease areas and technologies, as well as facilitating decision making when resources are scarce. Additionally, EQ-5D is recommended as the measure of choice for elicitation of health utilities by a number of HTA bodies in Europe,¹² including NICE in the UK.³⁹ Some HTA bodies (eg, Haute Autorité de Santé [HAS] – The French National Authority for Health – in France; the Canadian Agency for Drugs and Technologies in Health [CADTH] in Canada) are less stringent and support the use of other indirect measures, such as HUI, SF-6D, and 15D.^{40–42} In this literature review, no publication using HUI was identified. Only one publication mentioned 15D; however, the authors did not obtain values during their study but used a mapping algorithm previously developed for gastric cancer⁴³ to map EORTC QLQ-C30 obtained in their study to both 15D and EQ-5D.³⁰

Generic utility instruments address some of the practical difficulties of conducting direct elicitation exercises and the utilities can be used to compare QALYs gained for interventions across different patient groups and diseases. However, they may lack sensitivity in specific disease contexts, are difficult to apply to acute conditions, and there is evidence of ceiling (EQ-5D) and floor (SF-6D) effects. In addition, they can generate different estimates for the same condition, which is related to the differences in their valuation methods and scoring algorithms.⁴⁴

A few HTA bodies (eg, those in Denmark and Sweden) recommend use of the direct utility measures TTO or SG.¹² In general, health economists support the use of TTO and

SG over VAS. However, there are limitations associated with both. The SG approach can be relatively time consuming, while respondents can also have difficulty in understanding the concept of probabilities. Similarly, although the TTO represents a reliable and practical compromise, the trade-off concept can also be difficult for many people to understand.⁴⁴ Of these, the choice of method matters as the differences in theory and approach can lead to differences in utility valuation. For example, a review of utilities by Morimoto and Fukui⁴⁵ across 907 chronic and 86 acute health states reported a clear trend of VAS yielding the lowest and SG yielding the highest utility values for the same health states, with TTO lying in between.⁴⁵

The evidence showed that the disease-specific HRQOL instruments, FACT-G, FACT-B, EORTC QLQ-C30, and EORTC QLQ-BR32, were only used alongside EQ-5D. In most cases, these instruments conveyed HRQOL data rather than eliciting health utilities.

One approach to transform responses of disease-specific HRQOL instruments to utilities is mapping to generic measures. Authors of a few identified publications have explored this approach successfully, generally mapping disease-specific HRQOL instruments to EQ-5D.^{24–26} Mapping approaches are accepted by HTA bodies in several European countries (eg, England, Scotland, Italy, and Norway) in cases where there are no other data available.¹² In cases where mapping is used, the preferred approach by NICE and SMC is to map to EQ-5D.^{39,46} However, other European countries (eg, France) advise against mapping due to the uncertainties of mapping functions.¹² Among the identified HTA submissions to AWMSG, NICE, or SMC, only one used a mapping approach.³⁴ Two other HTA submissions were critiqued by NICE for not attempting mapping despite manufacturers reporting HRQOL data using EORTC QLQ-C30 or FACT-B during clinical development.^{32,35} In one case, it was highlighted that no HRQOL data were obtained during the trial.³⁷ NICE conducted a pilot study for the feasibility of obtaining robust EQ-5D data for patients with breast cancer in UK clinical practice.⁴⁷ Even though the study showed that it was feasible to collect data in such a setting, the logistics were complex and the authors recognized the merits of obtaining utility data from published estimates and trial data.

In the identified publications, several factors that affect utilities were reported, including sociodemographic characteristics of the study population (eg, age, income, and education), disease or health states, elicitation method, and country settings, which ultimately influence the decision making

process. During health economic evaluation, utility values are frequently taken from published literature. HTA bodies such as NICE and SMC emphasized that such an approach should be undertaken with diligent care; if possible, published utilities should be age-matched to the relevant tariff score, and the health states used when generating utility values should match that of the trial population. In addition, most HTA bodies have their country-specific requirements for elicitation methods (direct or indirect), value sets when using indirect elicitation methods, and use of mapping algorithms.¹²

The literature review was restricted to advanced/metastatic breast cancer and publications in English language of the past 10 years (January 2005–March 2015). This approach might have limited the number of publications identified. In addition, publications that used utility values reported in the literature were excluded as these did not add to the evidence base. The second aim of this literature review was to understand how these factors may influence future economic evaluations of metastatic/advanced cancer therapies. However, only a few manufacturer submissions were identified during the study time frame, limiting data availability from the reimbursement perspective and generalizability. Furthermore, out of the identified eight submissions to AWMSG, NICE, or SMC, seven therapies were not recommended; therefore, critique on the utility part within the submission was limited. Payer and decision maker perspectives outside of HTA bodies were not a focus of this review but undoubtedly could add another dimension when considering choice of utility elicitation.

Conclusion

Based on the results of this literature review, health utility elicitation methods varied widely across the targeted review for advanced/metastatic breast cancer. EQ-5D was the most commonly used measure, with the direct utility measures SG and TTO also highly represented in the review; this is in line with many European guidelines on health economic evaluations and recommendations from HTA bodies. Although a number of cancer-specific instruments were utilized, there is a lack of publications and HTA submissions reporting advanced/metastatic breast cancer health state utilities derived from breast cancer-specific instruments. In addition to choice of elicitation method, other factors – such as socio-demographic characteristics of the study population, disease or health states, and country settings – need to be taken into consideration when deriving health utilities for policy decision makers. Additional qualitative research discussing advanced/metastatic breast cancer health state utilities from

a payer and/or reimbursement decision maker perspective may offer additional insights.

Acknowledgments

The study was funded by Novartis and conducted by Adelphi Values. The authors acknowledge Darren Joe (of Adelphi Values) for help with data analysis and medical writing.

Author contributions

JC and VW participated in the study conception and design, analysis and interpretation of literature, write up and review of the manuscript for important intellectual content, and approved the manuscript for publication. YH participated in the study conception and design, reviewed, and approved the final version of the manuscript. All authors contributed toward data analysis, drafting and critically revising the paper and agree to be accountable for all aspects of the work.

Disclosure

JC and VW were employees of Adelphi Values at the time the research was conducted. YH is currently an employee of Novartis. The authors report no other conflicts of interest in this work.

References

- DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. *CA Cancer J Clin*. 2014;64(1):52–62.
- Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. *Eur J Cancer*. 2013;49(6):1374–1403.
- Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2012; 23(suppl 7):vii11–vii19.
- Donovan D. Metastatic breast cancer epidemiology and management with a focus on taxanes. *Clin J Oncol Nurs*. 2013;17(Suppl):5–8.
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. *Lancet*. 2005;365(9472):1687–1717.
- Bishop JF, Dewar J, Toner GC, et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. *J Clin Oncol*. 1999; 17(8):2355–2364.
- Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. *J Clin Oncol*. 1999;17(8):2341–2354.
- Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med*. 2001;344(11):783–792.
- Lidgren M, Wilking N, Jonsson B, Rehnberg C. Health related quality of life in different states of breast cancer. *Qual Life Res*. 2007;16(6):1073–1081.
- Phillips C. *What is a QALY?*. London: Hayward Medical Communications; 2009.
- Drummond MF. *Methods for the Economic Evaluation of Health Care Programmes*. Oxford: Oxford University Press; 2005.

12. EUnETHA. *Methods for Health Economic Evaluations – A Guideline Based on Current Practices in Europe*. Vol. 2014. Copenhagen: EUnETHA; 2014. Second draft.
13. National Institute of Health and Care Excellence (NICE). *Decision Support Unit (DSU) Technical Support Document 11: Alternatives to EQ-5D for Generating Health State Utility Values*. London: National Institute of Health and Care Excellence (NICE); 2011.
14. Frederix GW, Quadri N, Hovels AM, et al. Utility and work productivity data for economic evaluation of breast cancer therapies in the Netherlands and Sweden. *Clin Ther*. 2013;35(4):e1–e7.
15. Grimison PS, Simes RJ, Hudson HM, Stockler MR. Preliminary validation of an optimally weighted patient-based utility index by application to randomized trials in breast cancer. *Value Health*. 2009;12(6):967–976.
16. Haines TP, Sinnamon P, Wetzig NG, et al. Multimodal exercise improves quality of life of women being treated for breast cancer, but at what cost? Randomized trial with economic evaluation. *Breast Cancer Res Treat*. 2010;124(1):163–175.
17. Kuchuk I, Bouganim N, Beusterien K, et al. Preference weights for chemotherapy side effects from the perspective of women with breast cancer. *Breast Cancer Res Treat*. 2013;142(1):101–107.
18. Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J. Health state utilities for metastatic breast cancer. *Br J Cancer*. 2006;95(6):683–690.
19. Milne RJ, Heaton-Brown KH, Hansen P, Thomas D, Harvey V, Cubitt A. Quality-of-life valuations of advanced breast cancer by New Zealand women. *Pharmacoeconomics*. 2006;24(3):281–292.
20. Schleinitz MD, DePalo D, Blume J, Stein M. Can differences in breast cancer utilities explain disparities in breast cancer care? *J Gen Intern Med*. 2006;21(12):1253–1260.
21. Sherrill B, Amonkar MM, Stein S, Walker M, Geyer C, Cameron D. Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. *Br J Cancer*. 2008;99(5):711–715.
22. Shih V, Chan A, Xie F, Ko Y. Health state utility assessment for breast cancer. *Value Health Reg Issues*. 2012;1(1):93–97.
23. Zhou X, Cella D, Cameron D, et al. Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. *Breast Cancer Res Treat*. 2009;117(3):577–589.
24. Teckle P, McTaggart-Cowan H, Van der Hoek K, et al. Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D. *Health Qual Life Outcomes*. 2013;11:203.
25. Kim EJ, Ko SK, Kang HY. Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients. *Qual Life Res*. 2012;21(7):1193–1203.
26. Crott R, Briggs A. Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. *Eur J Health Econ*. 2010;11(4):427–434.
27. Mansel R, Locker G, Fallowfield L, Benedict A, Jones D. Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial. *Br J Cancer*. 2007;97(2):152–161.
28. Dranitsaris G, Cottrell W, Spirovski B, Hopkins S. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer. *J Oncol Pharm Pract*. 2009;15(2):67–78.
29. Cheng TF, Wang JD, Uen WC. Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer. *BMC Cancer*. 2012;12:33.
30. Bastani P, Kiadaliri AA. Cost-utility analysis of adjuvant therapies for breast cancer in Iran. *Int J Technol Assess Health Care*. 2012;28(2):110–114.
31. All Wales Therapeutics and Toxicology Centre. AWMSG Secretariat Assessment Report. Lapatinib (Tyverb®) 250 mg film-coated tablets. Report Ref. 178. Penarth, Vale of Glamorgan; 2013.
32. National Institute of Health and Care Excellence (NICE). NICE technology appraisal guidance 214. Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer. London: NICE; 2014.
33. National Institute of Health and Care Excellence (NICE). NICE technology appraisal guidance 239. Fulvestrant for the treatment of locally advanced or metastatic breast cancer. London: NICE; 2011.
34. National Institute of Health and Care Excellence (NICE). NICE technology appraisal guidance 257. Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptorpositive breast cancer that overexpresses HER2. London: NICE; 2012.
35. National Institute of Health and Care Excellence (NICE). NICE technology appraisal guidance 295. Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptorpositive breast cancer after endocrine therapy. London: NICE; 2013.
36. Scottish Medicines Consortium (SMC). SMC No. (726/11) Eisai Ltd. Eribulin 0.44mg/mL solution for injection (Halaven®). Glasgow: SMC; 2011.
37. National Institute of Health and Care Excellence (NICE). NICE technology appraisal guidance 250. Eribulin for the treatment of locally advanced or metastatic breast cancer. London: NICE; 2012.
38. National Institute of Health and Care Excellence (NICE). NICE technology appraisal guidance 263. Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer. London: NICE; 2012.
39. National Institute of Health and Care Excellence (NICE). Decisions Support Unit (DSU) technical support document 8: an introduction to the measurement and valuation of health for NICE submissions. London: NICE; 2011.
40. Pharmaceutical Benefits Advisory Committee (PBAC). Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.3). Barton ACT: Commonwealth of Australia; 2008.
41. Canadian Agency for Drugs Technologies in Health (CADTH). Guidelines for the economic evaluation of health technologies: Canada; 2006.
42. López-Bastida J, Oliva J, Antoñanzas F, et al. Spanish recommendations on economic evaluation of health technologies. *Eur J Health Econ*. 2010;11(5):513–520.
43. Kontodimopoulos N, Aletras V, Paliouras D, Niakas D. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments. *Value Health*. 2009;12:1151–1157.
44. Tolley K. *What are Health Utilities*. London: Hayward Medical Communications; 2009.
45. Morimoto T, Fukui T. Utilities measured by rating scale, time trade-off, and standard gamble: review and reference for health care professionals. *J Epidemiol*. 2002;12(2):160–178.
46. Scottish Medicines Consortium (SMC). *Guidance to Manufacturers for Completion of New Product Assessment Form (NPAF)*. Glasgow: Scottish Medicines Consortium (SMC); 2014.
47. National Institute of Health and Care Excellence (NICE). Report by the Decision Support Unit (DSU): Effects of cancer treatment on quality of life (ECTQoL): Final results. London: NICE; 2014.

ClinicoEconomics and Outcomes Research**Dovepress****Publish your work in this journal**

ClinicoEconomics & Outcomes Research is an international, peer-reviewed open-access journal focusing on Health Technology Assessment, Pharmacoeconomics and Outcomes Research in the areas of diagnosis, medical devices, and clinical, surgical and pharmacological intervention. The economic impact of health policy and health systems

organization also constitute important areas of coverage. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/clinicoeconomics-and-outcomes-research-journal>